- Home
- Z vs NBIX Comparison
Z vs NBIX Comparison
Compare Z & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- Z
- NBIX
- Stock Information
- Founded
- Z 2004
- NBIX 1992
- Country
- Z United States
- NBIX United States
- Employees
- Z N/A
- NBIX N/A
- Industry
- Z Business Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- Z Consumer Discretionary
- NBIX Health Care
- Exchange
- Z Nasdaq
- NBIX Nasdaq
- Market Cap
- Z 15.3B
- NBIX 12.8B
- IPO Year
- Z 2011
- NBIX 1996
- Fundamental
- Price
- Z $62.63
- NBIX $118.46
- Analyst Decision
- Z Buy
- NBIX Buy
- Analyst Count
- Z 21
- NBIX 24
- Target Price
- Z $60.84
- NBIX $163.91
- AVG Volume (30 Days)
- Z 3.0M
- NBIX 789.6K
- Earning Date
- Z 11-06-2024
- NBIX 10-30-2024
- Dividend Yield
- Z N/A
- NBIX N/A
- EPS Growth
- Z N/A
- NBIX 89.41
- EPS
- Z N/A
- NBIX 3.29
- Revenue
- Z $2,071,000,000.00
- NBIX $2,119,500,000.00
- Revenue This Year
- Z $15.89
- NBIX $25.96
- Revenue Next Year
- Z $13.75
- NBIX $16.41
- P/E Ratio
- Z N/A
- NBIX $35.94
- Revenue Growth
- Z 9.40
- NBIX 26.69
- 52 Week Low
- Z $33.80
- NBIX $103.63
- 52 Week High
- Z $68.73
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- Z 53.21
- NBIX 49.83
- Support Level
- Z $59.19
- NBIX $111.14
- Resistance Level
- Z $64.34
- NBIX $120.11
- Average True Range (ATR)
- Z 2.03
- NBIX 2.12
- MACD
- Z -0.42
- NBIX 1.45
- Stochastic Oscillator
- Z 50.44
- NBIX 81.99
About Z Zillow Group Inc. Class C Capital Stock
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.